SCHEMBL14322202

SCHEMBL14322202

CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSC(=O)c3ccccc3)CS[C@H]12)c1csc(N)n1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.81
▸ NR1I2 O75469 6/20 0.75
▸ HTR2C P28335 1/20 0.75
▸ MAPT P10636 5/20 0.72
▸ PPARG P37231 2/20 0.72
▸ SLC22A6 Q4U2R8 2/20 0.72
▸ SLC22A8 Q8TCC7 2/20 0.72
▸ SLC22A11 Q9NSA0 2/20 0.72
▸ ALB P02768 1/20 0.72
▸ PGR P06401 3/20 0.71
▸ DAO P14920 1/20 0.69
▸ SNCA P37840 1/20 0.69
▸ CYP2J2 P51589 1/20 0.69
▸ ABCC4 O15439 2/20 0.68
▸ TDP1 Q9NUW8 6/20 0.62
▸ APEX1 P27695 3/20 0.62
▸ HSD17B10 Q99714 3/20 0.62
▸ ALDH1A1 P00352 2/20 0.62
▸ POLB P06746 2/20 0.62
▸ RECQL P46063 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14331136 1.00 KMT2A (0.81) KMT2ANR1I2HTR2CMAPTPPARG
SCHEMBL14321878 1.00 KMT2A (0.81) KMT2ANR1I2HTR2CMAPTPPARG
SCHEMBL14321875 1.00 KMT2A (0.81) KMT2ANR1I2HTR2CMAPTPPARG
SCHEMBL23043566 0.90 NR1I2 (0.77) KMT2ANR1I2HTR2CMAPTPPARG
SCHEMBL23051167 0.90 NR1I2 (0.77) KMT2ANR1I2HTR2CMAPTPPARG
Ceftiofur SCHEMBL332042 0.90 KMT2A (1.00) KMT2ANR1I2HTR2CMAPTPPARG
Ceftiofur SCHEMBL12727853 0.90 KMT2A (1.00) KMT2ANR1I2HTR2CMAPTPPARG
Ceftiofur SCHEMBL332041 0.90 KMT2A (1.00) KMT2ANR1I2HTR2CMAPTPPARG
Ceftiofur SCHEMBL9367220 0.90 KMT2A (1.00) KMT2ANR1I2HTR2CMAPTPPARG
Ceftiofur SCHEMBL10296647 0.90 KMT2A (1.00) KMT2ANR1I2HTR2CMAPTPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120329770-A1 CEPHALOSPORIN DERIVATIVES USEFUL AS BETA-LACTAMASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF DMITRIENKO GARY IGOR (CA) 2012-12-27 — — US disclosed
US-20120329770-A1 CEPHALOSPORIN DERIVATIVES USEFUL AS BETA-LACTAMASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF DMITRIENKO GARY IGOR (CA) 2012-12-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329770-A1 CEPHALOSPORIN DERIVATIVES USEFUL AS BETA-LACTAMASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CMBL, PEPD, BCHE KMT2A 2026/4885NR1I2 3438/4885HTR2C 3175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback